Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2700219 | 0.80 | ERN1 (0.39) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL17462539 | 0.73 | BACE1 (0.34) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL1620964 | 0.71 | ALDH1A1 (0.41) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL1620152 | 0.66 | ALDH1A1 (0.42) | TRIM24TRIM33 | |
| SCHEMBL2597207 | 0.65 | ERN1 (0.58) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL23850354 | 0.65 | ERN1 (0.47) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL31680230 | 0.65 | PRKDC (0.37) | ERN1 | |
| SCHEMBL19643051 | 0.65 | PRKDC (0.37) | ERN1 | |
| SCHEMBL28607913 | 0.64 | PRKDC (0.48) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL1619656 | 0.64 | ALDH1A1 (0.56) | ERN1TRIM24TYRTRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194046-B1 | Triazolone derivative | EISAI R&D MAN CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| EP-2194046-A1 | Triazolone derivative | Eisai R&D Management Co., Ltd. (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2000465-A1 | TRIAZOLONE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | ERN1 1107/4885TRIM24 3275/4885TYR 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.